WNT/β-catenin pathway activation in hepatocellular carcinoma: a clinical perspective

Li Ma
Wei Wei
Mei-Sze Chua
Samuel So
Asian Liver Center and Department of Surgery, Stanford University School of Medicine, Stanford University, Stanford, CA, USA

Abstract: Hepatocellular carcinoma (HCC) is a significant global health concern which requires multidisciplinary approaches in its management. However, apart from surgical resection of the tumor, molecularly targeted therapeutics remains limited to sorafenib. New targets and drugs are urgently needed to broaden the currently limited treatment options for HCC to allow more efficacious clinical interventions and ultimately to improve the overall survival of HCC patients. The WNT/β-catenin pathway controls multiple biological functions throughout embryonic development and adult homeostasis; its dysregulation underlies a wide range of pathologies including cancer. In particular, many lines of evidence suggest that hyperactivation of this pathway is associated with the initiation and development of HCC. The critical role of the WNT to WNT/β-catenin pathway in HCC lends itself to rationally designed approaches to intervene with various aberrant loci along its signaling cascade to achieve therapeutic effects in HCC. Here, we review the current state of knowledge on WNT/β-catenin pathway deregulation in HCC, and how this pathway may be exploited for therapeutic interventions.

Keywords: WNT/β-catenin signaling, hepatocarcinogenesis, β-catenin/TCF complexes, targeted therapy

Pathophysiology of liver cancer
Hepatocellular carcinoma (HCC), the most common adult liver malignancy, is the sixth most common cancer and the third most frequent cause of cancer-related death worldwide.1 Most HCC cases (80%) occur in Eastern and Southeastern Asia, and sub-Saharan Africa, where the dominant risk factor is chronic infection with hepatitis B virus (HBV), together with exposure to aflatoxin B1. The relative risk of developing HCC is 100 fold among chronic HBV carriers compared with noncarriers.2 Most cases of chronic HBV infection occur in early childhood.3 The main pathogenic mechanisms for HBV-associated HCC are immune-mediated chronic liver damage, HBV genome integration, and the HBV X protein (HBx)-associated oncogenic transformation.4

In recent years, the incidence of HCC has been increasing in developed countries, including North America, Europe, and Japan, where the dominant risk factor is chronic infection with hepatitis C virus (HCV), together with other risk factors, such as alcohol abuse and nonalcoholic fatty liver disease.2,3 The relative risk of developing HCC is 15–20 fold in HCV carriers compared with noncarriers; the risk is increased in HCV carriers with cirrhosis.5 The main pathogenic mechanisms for HCV-associated HCC are immune-mediated chronic liver damage, and non-structural proteins NS3- and NS5-associated oncogenic transformation.6

Correspondence: Mei-Sze Chua
Asian Liver Center and Department of Surgery, Stanford University School of Medicine, Stanford University, 1201 Welch Rd, MSLS Building, Stanford, CA 94305-5655, USA
Tel +1 650 724 3525
Fax +1 650 723 0006
Email mchua@stanford.edu
Long-term, chronic, viral hepatitis caused by either virus usually leads to the progression of cirrhosis, which is present in 80%–90% of HCC patients. Cirrhosis reduces hepatic functional reserve, which results in symptoms such as portal hypertension and ascites. Most patients die directly from cirrhosis in the advanced stage. Moreover, cirrhotic patients have a higher risk of developing HCC with an annual incidence of 2.0%–6.6%, compared with noncirrhotic patients with an annual incidence of 0.4%.^3^

**Current treatment options and patient outcomes**

Surgical resection, local ablation, and liver transplantation are curative options when the tumor is detected in the early stage (<20% of HCC patients). Patients with early stage disease who receive surgical resection and local ablation have 5-year survival rates of 60%–70%.^2^ However, even in developed countries, only 25% of these early stage patients are suitable for these interventions due to restrictions imposed by tumor size, liver function impairment, and portal hypertension. Moreover, approximately 70% of patients develop recurrent tumors after resection and ablation within 5 years, which usually arises within the first 2 years. As the most promising curative treatment, liver transplantation offers 4-year survival of 75% for selected patients, with recurrence rates below 15%.^1,11^ However, patients have to be carefully selected, and transplantation is limited due to shortage of organ donation.

Patients with intermediate-stage HCC are asymptomatic, with multinodular tumors but without vascular invasion or extrahepatic spread, and are candidates for transarterial chemoembolization (TACE).^13^ Conventional TACE provides locoregional treatment with intra-arterial infusion of conventional antineoplastic drugs such as doxorubicin or cisplatin, followed by embolization of the blood vessel with embolic agents, and increases median survival time by 20–25 months. However, conventional TACE comes with strong systemic toxicity, which has been reduced by improvements in embolization devices such as drug elution beads. Even so, systemic toxicity remains a severe problem for patients with limited hepatic functional reserve as conventional antineoplastic drugs are nonselective.

Most HCC patients remain asymptomatic until the disease is far advanced. Patients with advanced-stage HCC present with cancer-related symptoms such as pain or malaise, together with evidence of vascular invasion or extrahepatic spread. These patients are candidates for systemic treatment with small molecule antineoplastic drugs such as tyrosine kinase inhibitors (TKI).^17^ Sorafenib (Nexavar®) (Bayer; Leverkusen, North Rhine-Westphalia, Germany; and Onyx Pharmaceuticals; South San Francisco, CA, USA), the only TKI approved by the US Food and Drug Administration for HCC therapy,^18^ is the standard of care for patients with advanced HCC. Sorafenib targets tyrosine kinases and blocks different signaling pathways, including those that regulate cell proliferation (via RAS mitogen-activated protein kinase [MAPK]) and angiogenesis (via vascular endothelial growth factor receptor and platelet derived growth factor receptor).^18^ Phase III clinical trial indicated that sorafenib treatment increased survival time of patients with advanced HCC from 7.9 to 10.7 months only. Despite the recent development of more TKIs for advanced HCC treatment, none has been shown to be more effective than sorafenib in prolonging patients’ survival, underscoring the need for more efficacious, molecularly-targeted drugs.

The poor prognosis of patients with intermediate-stage and advanced stage HCC (>80% of HCC patients) prompts the identification of new therapeutic targets and the development of new therapeutic approaches for its treatment. Major signaling pathways that are critical to the complex and multistep process of hepatocarcinogenesis have recently been identified, and the targeting of these pathways offers multiple opportunities to develop novel therapies for HCC. This review discusses the potential of targeting one of these major pathways, the WNT/β-catenin pathway, which is commonly deregulated in HCC.

**Introduction to the WNT/β-catenin pathway**

WNT is a hybrid name (for Wingless-related integration site) used to denote genes belonging to the int1/Wingless family, which replaced the original confusing nomenclature used for the Int genes. 2012 marks the 30th anniversary for the discovery of int1 (now known as WNT1). Int1 was first identified as an protooncogene transcriptionally activated by the mouse mammary tumor virus in mouse mammary tumor. So far, a family of 19 WNT-related genes has been characterized in vertebrates. WNTs are cysteine rich proteins around 40 kDa in size that participate in the complex WNT/β-catenin signaling cascade together with multiple other components. The WNT/β-catenin pathway plays crucial roles in many diverse cellular processes, including cell proliferation, cell fate decision, cell migration, and stem cell maintenance. As an important developmental signaling pathway, WNT/β-catenin pathway deregulation has been closely linked to cancer. For a history of this field and...
detailed biochemical mechanisms of this pathway, we refer the readers to recent reviews.27

The WNT/β-catenin pathway can be classified into canonical (β-catenin dependent) and noncanonical (β-catenin independent) pathways. WNT proteins trigger the signaling cascades in both these pathways by binding to seven-transmembrane frizzled receptors (FZD) and their coreceptors, the low density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), or the orphan receptor tyrosine kinase Ror2, respectively.28-30 In the inactivated state, β-catenin is attached to cadherin in maintaining cell–cell adhesion.31 In the canonical pathway, cytoplasmic β-catenin is sequestered by the multiprotein “destruction complex” that comprises adenomatous polyposis coli (APC), AXIN, and two kinases, glycogen synthase kinase-3 (GSK3) and casein kinase α/β, which sequentially phosphorylate β-catenin. Phosphorylated β-catenin is then recognized by the E3 ubiquitin ligase complex-gamma-TrCP and degraded in the cytoplasm by proteasomes. The overall net effect is low β-catenin levels within the cells. In the activated states or upon WNT binding, the dishevelled protein inhibits GSK3 phosphorylation activity, and the destruction complex becomes disintegrated. As a result, β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it enhances the transcriptional activity of β-catenin/TCF4 in the nucleus.43 For example, inactive truncations of APC occur in more than 80% of colon cancer patients44,45 and are associated with increased levels of active nuclear β-catenin,46 which represents the initial stage of oncogenic transformation.47 Mutations and defective truncations of AXIN1 and AXIN2, which are negative regulators of β-catenin, have also been reported in many cancers, including HCC,48 colon cancer,49 gastric tumor,50 adrenocortical carcinoma,51 and prostate cancer.52 Most of the mutation sites of AXIN genes exist in the β-catenin-interaction domain, resulting in up-regulation of transcriptional activity of β-catenin.53

In addition, activating mutations and truncations of CTNNB1 have been found in various types of cancers, such as colon cancer,54,55 melanoma,56 HCC,57,58 gastrointestinal tumors,59 thyroid cancers,60 ovarian tumor,61 sporadic desmoid tumor,62 and Wilms tumors.63 Most of the reported mutations of CTNNB1 are found in the N-terminus, which contains the phosphorylation sites Ser37, Thr41, and Ser45. These mutations in the N-terminus produce deletion of the N-terminal fragment or alter the phosphorylation of β-catenin, thereby protecting β-catenin from degradation by the “destruction complex.”42,53 Recently, another central factor of the WNT/β-catenin pathway, TCF4, has been reported with numerous alternative splice variants and frequent frameshift mutations in the C-terminus due to microsatellite instability in colon cancer,54,55 renal cell carcinoma,66 brain tumors,67 and gastric and endometrial carcinoma.68 These different isoforms and mutations reduce the ability of TCF4 to interact with the negative functional
regulator (c-terminal binding protein), thus enhancing the β-catenin/TCF4 transcriptional activity.65

Deregulations in ligand-dependent components of the WNT/β-catenin pathway

In the ligand-dependent WNT/β-catenin pathway, clinical studies have identified overexpression of most WNT proteins and FZD in various types of cancers, including breast cancer, 69 brain and neurological cancer, 70, 71 head and neck cancer, 72 acute lymphoblastic leukemia, 73 renal cell carcinoma, 74 prostate cancer, 75 esophageal carcinoma, 76 HCC, 77 colon cancer, 78 and synovial sarcomas. 79 Moreover, epigenetic studies have revealed that frequent promoter hypermethylation and gene silencing of the secreted frizzled related proteins (sFRPs) occur in colon cancer. 80 The downregulation of sFRPs has also been reported in melanoma, HCC, cervical carcinoma, breast carcinoma, ovary and kidney carcinomas. 81–85 Such epigenetic downregulation of sFRP genes frees active WNT proteins and allows constitutive WNT signaling in cancer cells. 86

Other regulators of the WNT/β-catenin signaling pathway

In addition to aberrant regulations directly involving components of the WNT/β-catenin signaling pathway, external regulators of this pathway also contribute toward its dysregulation that leads to cancer. For example, the transcription factor c-Myc is a classic downstream target gene of the WNT/β-catenin signaling pathway that was reported to transcriptionally repress the WNT inhibitors dickkopf (DKK) 1 and sFRP1, resulting in activated WNT/β-catenin signaling in breast cancer. 87 c-Myc was also reported to activate B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a polycomb group protein, that represses members of the DKK family. As a result of this repression, stimulated WNT/β-catenin pathway increases the c-Myc level, which further feeds into a feedback loop to activate the WNT/β-catenin signaling pathway. 88 Since c-Myc is also frequently overexpressed in other types of cancers, including HCC, it is likely that similar mechanistic activation of the WNT/β-catenin signaling pathway occurs and contributes toward carcinogenesis of these cancers.

Specific to HCC, HBx is a transactivator of several cellular signaling pathways, including the WNT/β-catenin pathway. A functional screen for host factors involved in the transactivational properties of HBx identified APC as a binding partner of HBx; the competitive binding of HBx to APC displaces β-catenin from the destruction complex, resulting in β-catenin upregulation in the nucleus and the activation of WNT/β-catenin signaling. 89 The HCV core protein was also found to significantly enhance TCF-dependent transcriptional activity induced by WNT3A in HCC cell lines. 90 It additionally increased β-catenin levels in the Huh7 HCC cell line through inactivation of GSK 3β. As a result, downstream target genes such as c-Myc and cyclin D1 were upregulated, leading to increased cell proliferation via the canonical WNT/β-catenin pathway.

Another class of external regulators is the micro ribonucleic acids (RNAs) (miRNAs), which are small noncoding RNAs between 20 to 23 nucleotides in length that regulate diverse cellular processes. They function through forming a complementary complex with the 3′-untranslated region of the target messenger RNA (mRNA), resulting in mRNA degradation or inhibition of mRNA translation, ultimately causing posttranslational gene silencing. 91 Many miRNAs have been reported to interact with members of the WNT/β-catenin signaling pathway. 92 eg, miR-200a directly targets the β-catenin mRNA to inhibit its translation thereby blocking WNT/β-catenin signaling. 93 The downregulation of miR-200a was correlated with upregulation of β-catenin in meningiomas, and in part contributes toward meningioma development. 94 Other miRNAs such as miR-21, miR-34a, and let-7e appear to regulate WNT1 at the functional level by controlling the amount of protein expressed. 95 Tumor suppressor oncomirs, mir-34a-3p and mir-34a-5p (which are direct downstream targets of tumor suppressor p53) were shown to directly target the untranslated regions of multiple genes in the WNT/β-catenin pathway, including WNT1, WNT3, LRP6, AXIN2, and β-catenin. 96 In colon cancer, miR-34a targets multiple binding sites within the 5′ and 3′ untranslated region of AXIN2, causing AXIN2 suppression and increasing nuclear GSK-3β abundance. 97 In HCC, miR-214 can either directly or indirectly target CTNNB1, thereby modulating the β-catenin transcriptional activity. 98 Additionally, HCV was reported to induce and upregulate miRNA-155 via nuclear factor-kappa beta; miRNA-155 then markedly suppressed APC levels to activate WNT/β-catenin signaling, promoting cell proliferation and tumor growth of HCC cells. 99

The WNT/β-catenin signaling pathway in HCC

Hyperactivation of the WNT/β-catenin signaling pathway is a major contributor to the pathogenesis of HCC. 99 Reported aberrant expressions of various components of this pathway in HCC are summarized in Table 1.
Genetic and epigenetic regulation of CTNNB1 encoding β-catenin

On average, approximately one third of HCC are shown to harbor mutations in CTNNB1, which encodes the β-catenin protein. Somatic mutations in components of the “destruction complex” result in aberrant WNT/β-catenin signaling pathway activation.

Expression of β-catenin in HCC may be subject to multilayered regulation other than mutation-mediated stabilization, as evidenced by greater percentage of β-catenin nuclear staining in comparison to lower β-catenin mutation rates detected in HCC patients. Indeed, CTNNB1 is targeted by miR-214, either directly or indirectly through enhancer of zeste homolog 2 (EZH2), a member of the polycomb repression complex 2 complex, leading to aberrant WNT/β-catenin signaling in HCC. More recently, Jung et al reported that upon WNT signaling activation, proliferating cell nuclear antigen (PCNA)-associated factor dissociates from PCNA and binds directly to β-catenin and then recruits EZH2 to the β-catenin transcriptional complex to specifically enhance WNT target gene transactivation, independently of EZH2’s methyltransferase activity.

Mutations in components of the “destruction complex”

AXIN determines the rate of β-catenin protein degradation and confers a tumor suppressor role. Functional studies demonstrated that conditional disruption of AXIN1 leads to development of liver tumors in mice, whereas restoration of AXIN1 by adenovirus-mediated gene transfer of wild-type AXIN1 suppressed HCC cell growth. Mutations in AXIN1 were detected in 6.2% of HCCs but not in low grade dysplastic nodules nor high grade dysplastic nodules, suggesting that β-catenin is neither an early event gene nor the gatekeeper gene in HCC development. However, another study concluded that β-catenin was accumulated in the cytoplasm and the nuclei in precancerous lesions of the liver and might contribute, at least in part, to hepatic tumor genesis.

Table 1 Clinical evidence of altered the WNT/β-catenin signaling pathway components in HCC

<table>
<thead>
<tr>
<th>Components of the WNT/β-catenin signaling pathway</th>
<th>Expression levels in HCC versus paratumor/normal liver tissues</th>
<th>Method of detection</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ligands</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WNT1</td>
<td>↑</td>
<td>Western blot</td>
<td>125,126</td>
</tr>
<tr>
<td>WNT3</td>
<td>↑</td>
<td>qRT-PCR</td>
<td>128</td>
</tr>
<tr>
<td>WNT5A</td>
<td>↓</td>
<td>IHC</td>
<td>129</td>
</tr>
<tr>
<td>WNT11</td>
<td>↓</td>
<td>qRT-PCR and Western blot</td>
<td>131</td>
</tr>
<tr>
<td>Antagonists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DKK1</td>
<td>↑</td>
<td>ELISA (serum)</td>
<td>133</td>
</tr>
<tr>
<td>DKK4</td>
<td>↓</td>
<td>qRT-PCR</td>
<td>136</td>
</tr>
<tr>
<td>DKK3</td>
<td>↓</td>
<td>qRT-PCR</td>
<td>134</td>
</tr>
<tr>
<td>WIF-1</td>
<td>↓</td>
<td>qRT-PCR</td>
<td>135</td>
</tr>
<tr>
<td>sFRP1,2,5</td>
<td>↓</td>
<td>Methylation</td>
<td>81</td>
</tr>
<tr>
<td>Receptors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FZD3</td>
<td>↑</td>
<td>IHC</td>
<td>138</td>
</tr>
<tr>
<td>FZD6</td>
<td>↑</td>
<td>IHC</td>
<td>138</td>
</tr>
<tr>
<td>FZD7</td>
<td>↑</td>
<td>qRT-PCR, IHC</td>
<td>77,138</td>
</tr>
<tr>
<td>LRP6</td>
<td>↑</td>
<td>qRT-PCR</td>
<td>140</td>
</tr>
<tr>
<td>“Destruction complex” components</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-catenin (CTNNB1)</td>
<td>↑</td>
<td>Sequencing/IHC</td>
<td>57,58,100,101</td>
</tr>
<tr>
<td>AXIN1 (AXIN1)</td>
<td>↓</td>
<td>Sequencing/IHC</td>
<td>48</td>
</tr>
<tr>
<td>APC (APC)</td>
<td>↓</td>
<td>Promoter methylation</td>
<td>121</td>
</tr>
</tbody>
</table>

Abbreviations: APC, adenomatous polyposis coli; DKK, dickkopf; ELISA, enzyme-linked immunosorbent assay; FZD, frizzled receptors; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; LRP, low density lipoprotein receptor-related protein; qRT-PCR, quantitative real time – polymerase chain reaction; sFRP, secreted frizzled related protein; WIF, WNT inhibitory factor.

Inconsistency exists in the purported role of CTNNB1 in HCC, and with poor prognosis of HCC patients.β WNT/β-catenin signaling pathway components in HCC are listed in Table 2. However, inconsistency exists in the purported role of β-catenin in disease initiation and progression of HCC. In a cohort consisting mostly of HBV-related HCC, CTNNB1 mutation was found in 16% of HCC patients, but CTNNB1 mutation was neither observed in low grade dysplastic nodules nor high grade dysplastic nodules, suggesting that β-catenin is neither an early event gene nor the gatekeeper gene in HCC development.β However, another study concluded that β-catenin was accumulated in the cytoplasm and the nuclei in precancerous lesions of the liver and might contribute, at least in part, to hepatic tumor genesis.
grade dysplastic nodules or high grade dysplastic nodules, suggesting that AXIN1 mutation might be a late event for malignant progression rather than an early genetic event involved in HCC initiation. The overall effects of AXIN1 mutations in HCC are impaired β-catenin phosphorylation and degradation (Table 2),\(^{48,105,116}\) resulting in β-catenin accumulation and activation of the WNT/β-catenin signaling pathway.

In contrast to CTNNBI and AXIN, APC is rarely mutated in HCC populations,\(^9\) being observed only occasionally as secondary mutations in patients with familial adenomatous polyposis or Gardner syndrome.\(^{117-119}\) Specific somatic biallelic inactivation of the APC gene was first reported in a case of sporadic HCC, and it was associated with inability to phosphorylate and degrade β-catenin, and thus, malignant transformation via activation of the WNT/β-catenin pathway (Table 2).\(^{120}\) Instead, APC is frequently hypermethylated in HCC.\(^{121}\) Based on two independent genome-wide methylation profiling studies performed on HCC patients,\(^{122,123}\) APC appears to be one of the top five most frequently hypermethylated genes in HCC and may account for the major mechanism in the loss of APC function in HCC, especially in HBV-related HCC. When bisulfite sequencing by polymerase chain reaction was performed to analyze the methylation status of both sense and antisense strands of the APC gene in HCC, it was found that hypermethylation of the C—phosphate—G sites on the sense strand only is specific for HCC.\(^{124}\) This result accounted for the observed variations in the specificity of the methylation of the APC gene for HCC. Importantly, 40% of HCC patients with nondiagnostic levels of alpha-fetoprotein (AFP) (<20 ng/mL) presented with methylation of the sense strand of APC, suggesting that sense strand methylation of APC may be useful in conjunction with AFP for improved HCC diagnosis.

### Altered expression of WNTs and antagonists in HCC

Several WNT proteins have dysregulated expression in HCC. For example, WNT1 expression was elevated in both HBV- and HCV-related HCC.\(^{125,126}\) While it was observed to be upregulated by HCV core proteins,\(^{127}\) its regulation by HBV is less well established.\(^{125}\) In HBV-induced HCC, WNT3 and downstream β-catenin target genes were upregulated in tumor and peritumoral tissues compared to normal liver.\(^{128}\) Functional interaction between WNT3 and FZD7 was demonstrated to cause activation of the WNT/β-catenin signaling pathway in HCC cells,\(^{128}\) which may play a role during hepatocarcinogenesis. Compared to nontumor liver, WNT5a protein expression (as determined by immunohistochemistry) was increased in chronic hepatitis, cirrhosis, and dysplastic liver cells but reduced in HCC.\(^{129}\) WNT5a, which acts in the noncanonical pathway, functions as an antagonist of

### Table 2 Mutations of key components involved in the WNT/β-catenin pathway in HCC

<table>
<thead>
<tr>
<th>Gene</th>
<th>Mutations and truncations</th>
<th>Effect of functional alteration</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L30Q, D32G, D32C, D32V, G34V, I35S</td>
<td>Alter the ubiquitin DSG amino acid targeting sequence, and protect β-catenin from ubiquitin-mediated degradation. Keep β-catenin activity, and inhibit β-catenin phosphorylation by GSK3β, diminish β-catenin ubiquitin-mediated degradation.</td>
<td>48,105,116</td>
</tr>
<tr>
<td></td>
<td>del A5-A80, del S35-G38, del V22-Y64, del w25-i140</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AXIN1</td>
<td>D94A, L106R, F201C</td>
<td>Lack the binding motifs APC, and inhibit β-catenin phosphorylation and degradation.</td>
<td>48,105,116</td>
</tr>
<tr>
<td></td>
<td>G425S, G651S, P849T</td>
<td>Lack the binding motifs of GSK3β, β-catenin and other Axins, and inhibit β-catenin phosphorylation and degradation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1bp deletion (codon 302)</td>
<td>Result in frameshift, lack the binding motifs of GSK3β and β-catenin, and inhibit β-catenin phosphorylation and degradation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8bp deletion (codon 603-606)</td>
<td>Result in premature termination, interrupt its binding to GSK3 and β-catenin, and inhibit β-catenin phosphorylation and degradation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13bp deletion (codon 522-526)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25bp deletion (codon 481-489)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>codon 443; GAG-TAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>codon 284; TGG-TGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>codon 443; GAG-TAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>codon 682; GGA-TGA</td>
<td>Result in premature termination that lacks the β-catenin-binding motif, and inhibit β-catenin phosphorylation and degradation.</td>
<td>120</td>
</tr>
</tbody>
</table>

**Abbreviations:** APC, adenomatous polyposis coli; CK, casein kinase; DSG, disuccinimidyl glutarate; GSK, glycogen synthase kinase; HCC, hepatocellular carcinoma.
canonical WNT/β-catenin signaling in HCC cells, especially in poorly differentiated cell lines. Its reduced expression in HCC, therefore, allows uninhibited WNT/β-catenin signaling to promote cell proliferation. Additionally, the noncanonical WNT11 mRNA and protein levels are also downregulated in HCC. WNT11 has been implicated as a tumor suppressor during hepatocarcinogenesis because loss of expression promotes the malignant phenotype via both canonical and noncanonical WNT/β-catenin signaling pathways. Conversely, overexpression of WNT11 activates protein kinase C signaling, which then promotes phosphorylation and degradation of β-catenin and WNT/β-catenin signaling.

Overexpression of the WNT antagonist DKK1 in HCC patients was reported to correlate with β-catenin cytoplasmic/nuclear staining and to predict poor survival. The ability of DKK1 to inhibit the WNT/β-catenin pathway through a negative feedback loop seems to be abrogated in HCC, most likely because genetic alterations disrupt the central multi-protein complex that controls the stability of β-catenin. In a large cohort study, elevated DKK1 in serum was validated and suggested as complement to AFP in HCC diagnosis. Other WNT antagonists such as DKK3 and WNT inhibitory factor (WIF)-1 were found to be significantly reduced due to hypermethylation in HCC compared with adjacent noncancerous tissues and normal control tissues, and might contribute towards activated WNT/β-catenin signaling and HCC initiation. The mRNA expression of DKK3 in HCC was decreased as the pathological grade increased. Reduced expression of WIF-1 mRNA was detected in HCC, and this downregulation was generally dependent on the degree of methylation at its promoter region. In vitro assays indicated that WIF-1 can inhibit cell growth by blocking WNT signaling in HCC cells. Additionally, DKK4 acts as a negative regulator of the WNT/β-catenin pathway, and reduced expression of its mRNA was found in 47% (38/81) of HCC. Decreased expression of DKK4 was associated with β-catenin accumulation in HCC tissues. Ectopic expression of DKK4 in two HCC cell lines, PLC/PRF/5 (PLC) and MHCC97L (97L), attenuated β-catenin responsive luciferase activity and decreased both β-catenin and cyclin D1 protein levels. Additionally, overexpression of DKK4 negatively affected cell proliferation, colony formation, cell migration, and in vivo tumorigenicity.

The sFRPs also act as WNT antagonists. In HCC, methylation of sFRP genes is an early event in liver carcinogenesis. Ectopic expression of sFRPs downregulated TCF/LEF transcriptional activity in liver cancer cells, whereas overexpression of a mutant β-catenin and depletion of sFRP1 using small interfering RNA (siRNA) synergistically upregulated TCF/LEF transcriptional activity. Additionally, epigenetic silencing of sFRP1 induced by the HCV core protein may lead to the activation of the WNT/β-catenin pathway and could contribute to metastasis in HCC progression.

**Aberrant expression of WNT receptors**

WNT receptors FZD3 and FZD6 are upregulated in HCC. FZD7 was found to be overexpressed in nearly 90% of tumors during the early development of HCC, especially in those related to chronic HBV infection. FZD7 overexpression was observed to occur early in the disease process and contributed to stabilized wild-type β-catenin levels and enhanced tumor cell migration. Additional studies confirm that activated WNT3/FZD7 canonical pathway has a role in the early stages of hepatocarcinogenesis by promoting the acquisition of a malignant phenotype with features of epithelial-mesenchymal transition, although these cells lack tumor initiation ability in vivo.

The LRP6 coreceptor is frequently overexpressed (in about 45% of HCC patients), and its elevated expression contributes to hyperactivation of the WNT/β-catenin signaling pathway in human HCCs, with consequent elevated levels of β-catenin protein, enhanced cell proliferation, migration, and invasion in vitro as well as enhanced tumorigenicity in vivo.

**Targeting the WNT/β-catenin pathway in HCC**

Abundant evidence in clinical settings has implicated the critical role of aberrant WNT/β-catenin signaling in HCC initiation and development, underscoring the potential of targeting this pathway for therapeutic intervention of this typically hard-to-treat cancer. The WNT/β-catenin pathway is often considered difficult to drug due to the lack of obvious enzyme targets. Nevertheless, there has been a repertoire of small molecules and natural compounds reported to inhibit the WNT/β-catenin signaling pathway at multiple points along the pathway. For example, a panel of antibodies and biologics developed by OncoMed Pharmaceuticals (Redwood City, CA, USA) have already entered early phase clinical trials; of those, antibodies targeting FZD7/8 were found to inhibit tumor growth in multiple cancer types using human patient derived xenograft models to reduce tumor-initiating cell frequency and to exhibit synergistic activity with standard-of-care chemotherapeutic agents. Additionally,
Figure 1 Targeting the WNT/β-catenin pathway in HCC.

Notes: In normal liver cells (“WNT OFF” state), β-catenin is sequestered by the multiprotein “destruction complex” in the cytoplasm (which consists of APC, AXIN, GSK3 and CK1). The “destruction complex” sequentially phosphorylates β-catenin, which is then recognized by the E3 ubiquitin ligase complex-gamma-TrCP and is further degraded by proteasomes. In HCC cells (activated or “WNT ON” state), the protein dishevelled inhibits GSK3 phosphorylation activity and the “destruction complex” disintegrates. As a result, β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it interacts with TCF4/LEF to transcriptionally activate downstream target genes. Investigational agents targeting various components that have been tested in HCC are indicated in red boxes.

Abbreviations: APC, adenomatous polyposis coli; AXIN, ; CK1, casein kinase; epCAM, epithelial cell adhesion molecule; FZD, frizzled receptors; GSK3, glycogen synthase kinase-3; TCF, T-cell factor; GSK, glycogen synthase kinase; HCC, hepatocellular carcinoma; LRP, low density lipoprotein receptor-related protein; SiRNA, small interfering RNA; TCF4/LEF, T-cell factor 4/lymphoid enhancer-binding factor.

Table 3 Experimental approaches in targeting the WNT/β-catenin signaling pathway in HCC

<table>
<thead>
<tr>
<th>Target(s)</th>
<th>Drug</th>
<th>Cell line/animal model</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>WNT1</td>
<td>Anti-WNT1 antibody</td>
<td>HCC cell lines, xenograft</td>
<td>Suppressed cell proliferation and reduced tumor growth.</td>
<td>125</td>
</tr>
<tr>
<td>FZD7</td>
<td>sFZD7</td>
<td>HCC cell lines</td>
<td>sFZD7 dose-dependently decreased viability of three HCC cell lines.</td>
<td>148</td>
</tr>
<tr>
<td>FZD9</td>
<td>siRNA of FZD9</td>
<td>HCC cell lines</td>
<td>Reduced FZD9 significantly suppressed cell proliferation and cell motility in HCC cell lines.</td>
<td>150</td>
</tr>
<tr>
<td>FZD7</td>
<td>Small interfering peptides interfere with FZD7-DVL protein–protein interaction</td>
<td>HCC cell lines and transgenic mouse model of HCC</td>
<td>Induced cell viability via apoptosis in vitro and in vivo.</td>
<td>149</td>
</tr>
<tr>
<td>β-catenin</td>
<td>β-catenin siRNA</td>
<td>HCC cell lines</td>
<td>Decreased growth and survival.</td>
<td>152</td>
</tr>
<tr>
<td>β-catenin and TCF4/LEF complex</td>
<td>PKF118-310, PKF115-584 and CGP049090</td>
<td>HCC cell lines, xenograft</td>
<td>Decreased tumor growth.</td>
<td>151</td>
</tr>
</tbody>
</table>

Abbreviations: DVL, dishevelled; FZD, frizzled receptors; HCC, hepatocellular carcinoma; Refs, references; sFZD7, soluble ectodomain of the FZD7 receptor; siRNA, small interfering RNA; TCF4/LEF, T-cell factor 4/lymphoid enhancer-binding factor.
β-catenin (both wild-type and activated mutants) has been suggested as a prime target for therapeutic intervention. Current attempts in targeting WNT/β-catenin signaling in HCC using biologics and small molecules remain restricted to preclinical data, as summarized in Figure 1 and Table 3.

Targeting WNT ligands
Since WNT ligands are direct activators of the WNT/β-catenin pathway, preventing ligand–receptor interactions or neutralizing WNT activators represent straightforward therapeutic approaches to antagonize WNT/β-catenin signaling. WNT1 was found to be overexpressed in a subgroup of HCC patients. The inhibition of WNT1-mediated signal activation using a specific anti-WNT1 antibody effectively repressed HCC cell proliferation in vitro and in vivo, with accompanying decreases in β-catenin/TCF4 transcriptional activities and downregulation of target genes c-Myc, Cyclin D1, and survivin. WNT1 expression was also reported to be downregulated by miR-122, a liver-enriched miRNA frequently lost in a subset of primary HCC patients. The ectopic overexpression of miR-122 resulted in antitumor effects of reduced cell proliferation and enhanced cell apoptosis in HCC cell lines, suggesting that miR-122 may be potentially useful in blocking the functions of WNT1-mediated signaling.

Targeting WNT receptors
Targeting of FZD has also met with encouraging preclinical success. For example, a soluble ectodomain of the FZD7 receptor (sFZD7) was reported to inhibit WNT/β-catenin signaling, likely via competitive inhibition of WNT ligand binding to FZD7. Furthermore, sFZD7 sensitized HCC cells to doxorubicin, suggesting possible combination therapy with conventional chemotherapeutic agents in patients who are less responsive to these conventional agents. Nambotin et al additionally designed small interfering peptides that competitively antagonized the cytoplasmic domain of FZD7, which resulted in apoptosis of cells and slowed tumor progression in a HCC mouse model. Knockdown of FZD9 using siRNA was also shown to suppress proliferation and motility of hepatoma cells.

Targeting transcription complexes
β-Catenin, the multifunctional effector protein, complexes with the transcription cofactors TCF4/LEF in the final relay of signals in the WNT/β-catenin pathway. Targeting this complex provides the most specific means of halting the activation of downstream target genes. Wei et al showed that three small molecule antagonists of the TCF4/β-catenin complex (namely PKF118-310, PKF115-584, and CGP049090) significantly inhibited proliferation of HCC cells in vitro and delayed tumor growth in vivo. These effects were accompanied by decreased expressions of downstream target genes such as Cyclin D1 and survivin. Zeng et al showed that siRNA-mediated β-catenin knockdown in human HCC cells decreased growth and survival of these cells, regardless of mutations in the CTNNB1 gene. Likewise, Wang et al observed significantly suppressed cell proliferation and cell cycle arrest in HepG2 cells upon siRNA-mediated β-catenin knockdown, together with changes in apoptosis- and angiogenesis-related genes. These studies provide convincing proof-of-principle findings that inhibiting β-catenin and its interaction with TCF4/LEF are effective ways of thwarting the downstream effects of WNT/β-catenin signaling, regardless of CTNNB1 mutation status and, therefore, represent a feasible approach for treating the heterogeneous subtypes of HCC.

Targeting enzymes in the WNT/β-catenin pathway
Recently, targeting of tankyrase enzymes has emerged as a promising therapeutic approach in cancers that rely on the WNT/β-catenin pathway for their growth. Tankyrases are members of the poly(adenosine diphosphate-ribose) polymerase (PARP) family that have multiple functions in various cellular processes, including regulation of telomere length by interacting with the telomeric repeat binding factor 1, regulation of mitosis, and regulation of the posttranslational modification (PARsylation) that leads to AXIN1 degradation and eventual activation of the WNT/β-catenin pathway. In a large scale chemical screen for tankyrase inhibitors, Huang et al identified XAV-939 as a potent inhibitor of tankyrase 1 (TANK1/PARP5A) and tankyrase 2 (TANK2/PARP5B), which stabilized AXIN levels in colon cancer cell lines, thereby promoting degradation of β-catenin and inhibiting WNT/β-catenin signaling. A number of derivatives based on XAV-939 have since been synthesized by different groups and have demonstrated antitumor efficacy in breast, colon, and lung cancers. Through another chemical screen, Chen et al identified two new groups of chemical inhibitors of enzymes involved in the WNT/β-catenin pathway, known as inhibitors of WNT production (IWP) and inhibitors of WNT response (IWR). IWP compounds inhibit the activity of porcupine, a membrane-bound O-acyltransferase that is essential to WNT production (IWP) and inhibitors of WNT response (IWR). IWP compounds therefore block all WNT-dependent biochemical changes.
downstream of WNT ligand/receptor interaction. However, IWR compounds appear to only promote β-catenin destruction likely by promoting stability of AXIN-scaffolded destruction complexes. The efficacy of tankyrase inhibitors, IWPcs, and IWRs remain to be tested in HCC.

Other effects of targeting the WNT/β-catenin pathway in HCC

The WNT/β-catenin pathway plays integral roles in the development of the embryo as well as in the maintenance, self-renewal, and differentiation of adult mammalian tissue stem cells. Recent evidence suggests that aberrant regulation of this pathway in adult stem cells leads to neoplastic proliferation and tumor formation. Indeed, the WNT/β-catenin pathway has been implicated in the maintenance of “stem-like” properties of liver cancer stem cells (LCSCs). In particular, the LCSC marker epithelial cell adhesion molecule (EpCAM) has been reported to be a target gene of WNT/β-catenin signaling. Specifically, nuclear accumulation of β-catenin induced, whereas degradation of β-catenin or inhibition of TCF/β-catenin complex formation reduced, EpCAM gene expression in cultured normal human hepatocytes and HCC cell lines. Moreover, two TCF binding elements were identified in the EpCAM promoter. EpCAM+ HCC cells were more sensitive to TCF/β-catenin inhibitors than EpCAM− HCC in vitro, suggesting that EpCAM expression may allow effective stratification of patients with predicted pharmacologic responses to WNT/β-catenin signaling antagonists. In a separate study, the activation of WNT/β-catenin signaling enriched the EpCAM+ cell population in HCC cell lines, whereas RNA interference-based blockade of EpCAM attenuated the self-renewing, differentiation, and invasive abilities of these cells. Additionally, LCSCs that are enriched for the cell surface marker CD133 were found to express 21 proteins that are involved in the WNT/β-catenin pathway. WNT/β-catenin activity measured by TOPflash luciferase reporter assay (Millipore Corporation, Billerica, MA, USA) was concomitantly higher in the CD133+ cells compared to that in the CD133− cells isolated from the Huh7 HCC cell line. Thus, targeting the WNT/β-catenin pathway offers an indirect but effective way of eradicating the functions of at least two subpopulations of LCSCs, which may potentially inhibit hepatocarcinogenesis, recurrence, and also sensitize HCC cells to conventional radio- and chemotherapies.

Coincidentally, the WNT/β-catenin signaling pathway is associated with chemoresistance in HCC, and may in part mediate the chemoresistance of LCSCs. For example, positive EpCAM expression was observed only in nonresponders to interferon-alpha/5-fluorouracil therapy, suggesting that EpCAM is a potentially useful marker of resistance to such therapy. In vitro activation of WNT/β-catenin signaling by GSK-3 inhibitor (6-bromoindirubin-3'-oxime) was found to induce chemoresistance to interferon-alpha/5-fluorouracil. Additionally, cisplatin resistance in HCC was reported to be associated with an increase in miR-130a levels, which was shown to directly inhibit expression of tumor suppressor gene RUNX3, resulting in activation of WNT/β-catenin signaling and increased drug resistance. Overexpression of miR-130a contributed to cisplatin resistance in Huh7 cells, whereas knockdown of miR-130a overcame cisplatin resistance in cisplatin-resistant Huh7 cells. These data suggest that miR-130a/RUNX3/WNT/β-catenin signaling represents a novel pathway regulating chemoresistance, and offers a novel approach to sensitizing HCC cells to chemotherapy.

Perspectives and conclusion

Given the established role of WNT/β-catenin signaling in the initiation and development of HCC and its documented dysregulation in subsets of HCC patients, the targeting of multiple components of this pathway offers new molecularly targeted approaches for potentially more efficacious and personalized treatment of HCC patients. In support of this, recent experimental and preclinical studies with investigative agents targeting multiple points along this pathway have shown encouraging antitumor effects in HCC cells. However, rigorous and systematic evaluation of their safety, toxicity, and preclinical efficacies are warranted. Like other molecularly targeted therapies, toxicities may arise from off-target effects. For example, because β-catenin has important functions in cell adhesion, complete abrogation of β-catenin function may cause detrimental effects on cellular homeostasis. Also, normal organ/tissue turnover is highly dependent on the WNT/β-catenin signaling pathway; the inhibition of this pathway may cause potential toxicity in organs such as the gut and hair follicles. As demonstrated by a study using the tankyrase inhibitor XAV-939 in colon cancer cells, high doses resulted in severe intestinal damage. The heterogeneous pathophysiology of HCC also suggests that combined treatment of WNT/β-catenin pathway inhibitors and other conventional or molecularly targeted agents such as sorafenib may provide a more complete antitumor response. Of note, sorafenib was shown to modulate the WNT/β-catenin pathway and β-catenin level in HCC cell lines with dysregulated WNT/β-catenin signaling (characterized by upregulation of liver-specific WNT targets and nuclear β-catenin). It is probable that combined treatment of sorafenib with other
WNT/β-catenin inhibitors may enhance the current clinical efficacy of sorafenib.

Taken together, continued efforts in understanding the detailed molecular events underlying WNT/β-catenin-mediated hepatocarcinogenesis and in the design and development of inhibitors of this pathway will likely impact on the clinical management and outcome of HCC patients globally.

Disclosure
The authors report no conflicts of interest in this work.

References

Dovepress
WNT pathway in liver cancer

Gastrointestinal Cancer: Targets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 23-Sep-2019
For personal use only. www.dovepress.com

Dovepress


